Literature DB >> 11562838

[Fever of central origin during stroke].

A Morales-Ortiz1, M Jiménez-Pascual, J A Pérez-Vicente, A Monge-Arguiles, J Bautista-Prados.   

Abstract

INTRODUCTION: Fever appears in a fourth of stroke, approximately. Its origins, (the most of them are infectious) are unknown in a minority of the cases. Some hypotheses indicate that central mechanisms like hypothalamic lesions or segregation of endogenous pyrogens may be implicated.
OBJECTIVE: To evaluate the frequency of central fever during stroke and to notice if there are clinical differences between infectious and central origins of the fever. PATIENTS AND METHODS: 103 patients were evaluated prospectively, if someone had fever, an investigation about an infectious origin was made. We divided the fever patients into two groups: "infectious fever" and "fever without infection documented" and we analyzed the clinical differences between them.
RESULTS: 23% of the patients had fever, 33% without infection documented. This last group had earlier fevers. They had more clinical severity and more mortality. The fever was higher and it didn't response to the antipyretic treatment also. The others parameters didn't show any difference between the two groups.
CONCLUSION: The patients with fever without infection documented ( probably fever of central origin)had a defined model with its own characteristics, in a different way from infectious fever.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562838

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  2 in total

1.  Central hyperthermia treated with baclofen for patient with pontine hemorrhage.

Authors:  Hyun Cheol Lee; Jong Moon Kim; Jae Kuk Lim; Yoon Sik Jo; Shin Kyoung Kim
Journal:  Ann Rehabil Med       Date:  2014-04-29

2.  Effectively managing intractable central hyperthermia in a stroke patient by bromocriptine: a case report.

Authors:  Kuo-Wei Yu; Yu-Hui Huang; Chien-Lin Lin; Chang-Zern Hong; Li-Wei Chou
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-03       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.